Apricus Biosciences, Inc.
Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
SAN DIEGO, May 04, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' first quarter 2017 financial results will be released on Thursday, May 11, 2017 at 4:01 p.m. Eastern Time. Company management will host a conference call on Thursday, May 11, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 18008306. The live audio webcast can be accessed via the Investor Relations' section of Apricus' website at www.apricusbio.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. The archived webcast will remain available for 30 days following the live call.
About Apricus Biosciences, Inc .
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which Apricus owns worldwide rights.
For further information on Apricus, visit http://www.apricusbio.com .
Vitaros(TM) is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States. RayVa(TM) is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.
CONTACT: Institutional / Retail Investors: Matthew Beck email@example.com The Trout Group LLC (646) 378-2933
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Abeona Therapeutics Inc16.3.2018 22:34 | pressemeddelelse
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
Bromium16.3.2018 13:03 | pressemeddelelse
Up to $200 Billion in Illegal Cybercrime Profits Is Laundered Each Year, Comprehensive Research Study Reveals
Z-Wave Alliance16.3.2018 11:01 | pressemeddelelse
Z-Wave Alliance Dominates Building Automation Space at Light + Building 2018
RFA15.3.2018 13:02 | pressemeddelelse
RFA Names Richard Muckle as Head of Client Development for its EMEA Headquarter
Mitratech15.3.2018 13:02 | pressemeddelelse
Mitratech Strengthens Position in African Market with Union Systems Partnership
EchoMaster14.3.2018 21:07 | pressemeddelelse
EchoMaster Announces New Left-Turn Alarm System For UK Vehicles
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum